Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT02559492
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 90
- Registration Number
- NCT02553330
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT02456675
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT02431260
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 201
- Registration Number
- NCT02393248
- Locations
- 🇺🇸
Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT02355431
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 307
- Registration Number
- NCT02327078
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 176
- Registration Number
- NCT02318277
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02298153
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT02265510
- Locations
- 🇺🇸
Site 2, Nashville, Tennessee, United States